Prescient Therapeutics



Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

Prescient Therapeutics (ASX: PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center in New Haven, Connecticut (Yale) under the leadership of Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Category: Health & biotech
URL: http://www.ptxtherapeutics.com
Operational Status: Active
ASX Listing Code (if applicable): PTX
Year of Commencement: 2014
Address:

Level 4
100 Albert Road
South Melbourne VIC 3205

State: Victoria
Overseas Operations: No
Twitter:
Facebook:
Linkedin: https://www.linkedin.com/company/prescient-therapeutics/
Key Personnel:
Awards won:



Milestones:

No items found

Funding:

No items found

Company News:

No items found

NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking

Amount Seeking:
Type of capital raise:
Pre-money valuation:
ESIC Status: Eligibility unknown
ESIC Upload:
Future Intentions:
Investment Video:
Investment Pitchdeck:
Investment URL:
Investment Phone:
Investment Email: